PRESS RELEASE

PRESS RELEASE

View printer-friendly version << Back

Reminder: Novavax to Host an RSV F Vaccine Update Conference Call and Webcast on July 24, 2017 at 4:30 PM
-- Announce topline data from the Phase 2 Safety and Immunogenicity trial of the RSV F Vaccine in older adults
-- Provide an Update on the RSV F Vaccine Development Program

GAITHERSBURG, Md., July 21, 2017 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced it will host a conference call and webcast on Monday, July 24, 2017, at 4:30 p.m. ETNovavax anticipates receiving results and announcing topline data from its Phase 2 safety and immunogenicity trial of the RSV F Vaccine in older adults (60 years of age and older).  In addition, management will provide an update on its prior Phase 2 and Phase 3 clinical trials in older adults, as well as its RSV Phase 3 clinical trial for infants via maternal immunization, known as Prepare™, which continues to experience significant acceleration in enrollment and enhanced momentum heading into its third global season.

Preliminary webcast agenda:

  1. Announce topline data from the Phase 2 safety and immunogenicity trial in Older Adults
  2. Provide additional findings from prior Phase 2 and Phase 3 clinical trials in Older Adults
  3. Update on the Prepare™ trial for Infants via Maternal Immunization

Conference call details are as follows:

Date:

Monday, July 24, 2017

Time:

4:30 p.m. U.S. Eastern Time (ET)

Dial-in number:

(877) 212-6076 (Domestic) or (707) 287-9331 (International)

Passcode:

54820069

Webcast:

www.novavax.com, "Investors"/ "Events"

Conference call and webcast replay:

Dates:

Starting at 7:30 p.m. ET, July 24, 2017, until 7:30 p.m. ET, July 31, 2017 

Dial-in number:

(855) 859-2056 (Domestic) or (404) 537-3406 (International)

Passcode:

54820069

Webcast:

www.novavax.com, "Investors"/ "Events", until October 24, 2017

About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage biotechnology company committed to delivering novel products to prevent a broad range of infectious diseases. Its recombinant nanoparticles and Matrix-M™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines.

Contact:    

Investor Relations
Novavax, Inc.
Andrea N. Flynn, Ph.D.
Director, Investor Relations
ir@novavax.com
240-268-2000

Westwicke Partners
John Woolford
john.woolford@westwicke.com
443-213-0506

Media
Russo Partners, LLC
David Schull
Maggie Beller
david.schull@russopartnersllc.com 
maggie.beller@russopartnersllc.com 
212-845-4271  

View original content:http://www.prnewswire.com/news-releases/reminder-novavax-to-host-an-rsv-f-vaccine-update-conference-call-and-webcast-on-july-24-2017-at-430-pm-300492231.html

SOURCE Novavax, Inc.

This site uses cookies and similar technologies to provide you with our services, enhance the performance and functionality of our services, and analyze the use of our products and services. By clicking ‘Accept’ you are indicating your consent for us to place these cookies. For more information, please read our Privacy Policy or manage your cookie settings.

Accept